MatriSys Bioscience Revenue and Competitors
Estimated Revenue & Valuation
- MatriSys Bioscience's estimated annual revenue is currently $1.4M per year.
- MatriSys Bioscience's estimated revenue per employee is $155,000
Employee Data
- MatriSys Bioscience has 9 Employees.
- MatriSys Bioscience grew their employee count by 29% last year.
MatriSys Bioscience's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President, CEO and Director at MatriSys Bioscience, Inc. | Reveal Email/Phone |
2 | Founder and VP - Preclinical Sciences | Reveal Email/Phone |
MatriSys Bioscience Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is MatriSys Bioscience?
MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. MatriSys Bio's scientific approach is to rebalance the natural skin microbiome by application of microbial therapies -“Good Bugs†that selectively target skin pathogens -“Bad Bugsâ€. Our lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis (“ADâ€) market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. Our “Good Bugâ€, S. hominis, is highly potent against the “Bad Bugâ€, Staph. aureus, which has long been associated with AD. S. hominis does not affect other “Good Bugs†leading to the natural rebalance of the skin microbiome.
keywords:N/A
N/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in La Jolla
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | 125% | N/A |
#2 | $1.4M | 9 | 29% | N/A |
#3 | $1.6M | 10 | -9% | N/A |
#4 | $1.7M | 11 | 57% | N/A |
#5 | $1M | 12 | -33% | N/A |